Exicure (XCUR) closed at $0.90 on November 20, 2026, down 8.2% from the previous close, on volume of 29,751 shares (30-day average 82,371).
Data as of November 20, 2026.
Exicure Announces Strategic Expansion and Investment Agreement for X-CUE
TipRanks (Fri, 20-Nov 1:27 PM ET)
Exicure Announces Strategic Expansion into Parkinson's Disease
Globe Newswire (Fri, 20-Nov 1:00 PM ET)
Exicure Delays Quarterly Filing for Asset Review
TipRanks (Mon, 16-Nov 7:58 PM ET)
Exicure Announces Filing of Notification of Late Filing on Form 12b-25
Globe Newswire (Mon, 16-Nov 4:00 PM ET)
Exicure, Inc. Announces Agreement to Sell GPC-100 Program Assets to GPCRT Inc. for KRW 6.5 Billion
Globe Newswire (Tue, 10-Nov 3:50 PM ET)
Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders' Equity Requirement
Globe Newswire (Wed, 16-Sep 8:00 AM ET)
Market Chameleon (Tue, 9-Dec 4:52 AM ET)
Market Chameleon (Tue, 9-Dec 2:05 AM ET)
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
Exicure trades on the NASDAQ stock market under the symbol XCUR.
As of November 20, 2026, XCUR stock price declined to $0.90 with 29,751 million shares trading.
XCUR has a beta of -0.15, meaning it tends to be less sensitive to market movements. XCUR has a correlation of 0.00 to the broad based SPY ETF.
XCUR has a market cap of $5.89 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, XCUR traded as high as $36.00 and as low as $.78.
The top ETF exchange traded funds that XCUR belongs to (by Net Assets): VXF.
XCUR has underperformed the market in the last year with a return of -78.5%, while the SPY ETF gained +6.9%. In the last 3 month period, XCUR fell short of the market, returning -30.8%, while SPY returned -9.3%. However, in the most recent 2 weeks XCUR has outperformed the stock market by returning -5.2%, while SPY returned -6.2%.
XCUR support price is $.90 and resistance is $1.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XCUR shares will trade within this expected range on the day.